High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities
Lucia Chmelova (University of Cambridge)
Helen R. Davies (University of Cambridge)
Giuseppe Rinaldi (University of Cambridge)
Leon Wils (Netherlands Cancer Institute)
Daniella Black (University of Cambridge)
Yasin Memari (University of Cambridge)
Gene C.C. Koh (Sunway University, University of Cambridge)
Scott Shooter (University of Cambridge)
Lodewyk F.A. Wessels (Netherlands Cancer Institute, TU Delft - Electrical Engineering, Mathematics and Computer Science)
More Authors (External organisation)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
Ductal carcinoma in situ is a non-obligate precursor lesion of breast cancer. Often detected by mammography, most cases are managed through surgical and/or radiotherapy approaches. Today, it is not possible to predict which patients will progress to invasive disease. Here, we evaluate high-depth whole-genome sequenced ductal carcinoma in situ, enriched for high-grade clinical lesions, to understand whether deep WGS could reveal biological insights and/or personalized therapeutic vulnerabilities that may be targetable. We find genomic locations that are likely susceptible to producing the initiating lesion for structural variations prone to subsequent evolution, termed SHOREs. We additionally highlight individualized therapeutic potential that would otherwise not be appreciable without whole genome sequencing. We posit that holistic whole genome sequencing profiling could offer a more precise stratification approach, discerning higher-risk cases for prospective clinical studies on personalized therapies, from truly low-risk cases suitable for active monitoring.
help_outline